01 — The premise
Designed for a woman assumed to be finished
Transdermal estradiol patches were developed in the 1980s and 1990s, largely by men, for a patient understood as implicitly post-sexual.
Nothing about the size, the sound it makes, the residue it leaves or the aesthetic appeal has been revisited for forty years.
“I was 42 the first time a lover saw my patch. ‘Ew. What IS that?’
Humiliating.
Yet, it was ugly and itchy. I stopped wearing it and dealt with the symptoms.”
1 in 20 women reaches menopause before 45. They should wear a patch the longest, but no one designed something they’d wear.
02 — The problem
Every patch below delivers the same dose
Contact surface areas per prescribing information; drawn to scale.
Residue
A gray ring of adhesive and trapped lint builds over a 3–7 day wear cycle and resists soap.
Irritation
Application-site reactions are among the most commonly reported adverse events.
Status quo
Beige, translucent, unbranded. Conspicuously “invisible.”
03 — Why now
Three things changed at once
The warning came off
In November 2025 the FDA began removing the black box warnings that killed the category — cardiovascular disease, breast cancer, probable dementia.
The guidance moved
In October 2026 the American College of Physicians named hormone therapy first-line for hot flashes and night sweats. Guidance favors transdermal.
The stigma broke
Menopause moved from unmentionable to a mainstream cultural and commercial conversation in the past few years, with celebrity, media and venture attention following.
Demand is coming back with a vengeance. The products have not changed since the category collapsed twenty years ago.
50% of humans live a third of life in various stages of menopause.
The patch shouldn’t be ugly.
Kelly Weitzel · Iris Alonzo
hello@lepatch.io